• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CYP2A6 Gene Record

  • Summary
  • Interactions
  • Claims
  • CYP2A6 1548 Druggable Genome

    Alternate Names:

    1548
    CYTOCHROME P450 FAMILY 2 SUBFAMILY A MEMBER 6
    CYP2A6
    CPA6
    CYP2A
    CYP2A3
    CYPIIA6
    P450C2A
    P450PB
    122720
    2610
    ENSG00000255974
    OTTHUMG00000182713
    ENSG00000198470
    CYTOCHROME P450 2A6 (EC 1.14.14.1) (CYPIIA6) (COUMARIN 7-HYDROXYLASE) (IIA3) (CYP2A3) (P450(I)). [SOURCE:UNIPROT/SWISSPROT;ACC:P11509]
    P11509
    CP2A6_HUMAN
    CYTOCHROME P450 2A6
    PA121
    T06455

    Gene Info:

    Human Readable Name DRUGGABLE GENOME
    Interpro Name Cytochrome P450
    Uniprot Status Swiss-Prot
    Interpro Type Family
    Interpro Acc IPR001128
    Interpro Short Name Cyt_P450
    Uniprot Evidence 1: Evidence at protein level
    Human Readable Name CYTOCHROME P450
    Gene Biotype PROTEIN_CODING
    (4 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME
    CYTOCHROME P450
    ENZYME

    Publications:

    Simonsson US et al., 2003, Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9., Clin Pharmacol Ther
    Kerb R et al., 2009, Pharmacogenetics of antimalarial drugs: effect on metabolism and transport., Lancet Infect Dis
    Medhi B et al., 2009, Pharmacokinetic and toxicological profile of artemisinin compounds: an update., Pharmacology
    Veiga MI et al., 2009, Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam., Eur J Clin Pharmacol
    Elsherbiny DA et al., 2008, A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens., J Pharmacokinet Pharmacodyn
    Asimus S et al., 2008, Artemisinin and CYP2A6 activity in healthy subjects., Eur J Clin Pharmacol
    Li XQ et al., 2003, Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data., Eur J Clin Pharmacol
    Tani N et al., 2014, Rational design of novel CYP2A6 inhibitors., Bioorg Med Chem
    Komatsu T et al., 2000, Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4., Drug Metab Dispos
    Torchin CD et al., 1996, Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes., Drug Metab Dispos
    Di YM et al., 2009, Structure, function, regulation and polymorphism of human cytochrome P450 2A6., Curr Drug Metab
    Restrepo JG et al., 2009, Polymorphic drug metabolism in anaesthesia., Curr Drug Metab
    Kimber-Trojnar Z et al., 2003, Perspectives of losigamone in epilepsy treatment., Pol J Pharmacol
    Pearce RE et al., 2002, Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites., Drug Metab Dispos
    Ghodke Y et al., 2012, PharmGKB summary: zidovudine pathway., Pharmacogenet Genomics
    Chen W et al., 1998, Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6., Chem Res Toxicol
    Mazaleuskaya LL et al., 2015, PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses., Pharmacogenet Genomics
    Hazai E et al., 2002, Reduction of toxic metabolite formation of acetaminophen., Biochem Biophys Res Commun
    Bergen AW et al., 2015, Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption., PLoS One
    Oscarson M et al., 1998, Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase., FEBS Lett
    Hadidi H et al., 1997, A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin., Food Chem Toxicol
    Gao N et al., 2016, Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes., Eur J Pharm Sci
    Wang H et al., 2011, Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes., Pharmacogenomics
    Li L et al., 2006, New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes., Drug Metab Dispos
    Haberl M et al., 2005, Three haplotypes associated with CYP2A6 phenotypes in Caucasians., Pharmacogenet Genomics
    Fukami T et al., 2005, Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity., Drug Metab Dispos
    Kiyotani K et al., 2003, Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9)., Pharmacogenetics
    Yoshida R et al., 2003, Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro., Clin Pharmacol Ther
    Xu C et al., 2002, An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles., Biochem Biophys Res Commun
    Pitarque M et al., 2001, Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity., Biochem Biophys Res Commun
    Kitagawa K et al., 2001, CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity., J Biol Chem
    Meunier V et al., 2000, Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up., Xenobiotica
    Oscarson M et al., 1999, Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism., FEBS Lett
    Yamano S et al., 1990, The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes., Biochemistry
    Fukami T et al., 2005, A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity., Biochem Pharmacol
    Oscarson M et al., 2002, Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity., Hum Mutat
    Donato MT et al., 2000, CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers., Drug Metab Dispos
    Kitagawa K et al., 1999, The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP., Biochem Biophys Res Commun
    Tanii H et al., 2011, Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women., Eur J Clin Pharmacol
    Elens L et al., 2010, Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients., Pharmacogenomics
    Hirose T et al., 2010, Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer., Oncol Rep
    Djordjevic N et al., 2010, In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population., Eur J Clin Pharmacol
    Tan L et al., 2010, The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients., Clin Neurol Neurosurg
    Ishii Y et al., 2010, Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?, Cancer Chemother Pharmacol
    Murai K et al., 2009, Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes., Xenobiotica
    Kong SY et al., 2009, Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer., Pharmacogenomics
    di Iulio J et al., 2009, In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function., Pharmacogenet Genomics
    Arab-Alameddine M et al., 2009, Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals., Clin Pharmacol Ther
    Endo T et al., 2008, Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine., Pharmacogenet Genomics
    Fujita K et al., 2008, CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1., Cancer Sci
    Kaida Y et al., 2008, The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer., Clin Pharmacol Ther
    Fukami T et al., 2007, A novel duplication type of CYP2A6 gene in African-American population., Drug Metab Dispos
    Peamkrasatam S et al., 2006, In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais., Drug Metab Pharmacokinet
    Audrain-McGovern J et al., 2007, The role of CYP2A6 in the emergence of nicotine dependence in adolescents., Pediatrics
    Benowitz NL et al., 2006, CYP2A6 genotype and the metabolism and disposition kinetics of nicotine., Clin Pharmacol Ther
    Nakajima M et al., 2006, Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations., Clin Pharmacol Ther
    Nurfadhlina M et al., 2006, CYP2A6 polymorphisms in Malays, Chinese and Indians., Xenobiotica
    Minematsu N et al., 2006, Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms., Eur Respir J
    Malaiyandi V et al., 2006, Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy., Mol Psychiatry
    Huang S et al., 2005, CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents., Pharmacogenet Genomics
    Kimura M et al., 2005, Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans., Drug Metab Dispos
    Gambier N et al., 2005, Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort., Pharmacogenomics J
    Gyamfi MA et al., 2005, High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana., Eur J Clin Pharmacol
    Fukami T et al., 2004, A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo., Clin Pharmacol Ther
    Schoedel KA et al., 2004, Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians., Pharmacogenetics
    Fujieda M et al., 2004, Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers., Carcinogenesis
    Yamanaka H et al., 2004, Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted., Eur J Pharm Sci
    Iwahashi K et al., 2004, Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior., Neuropsychobiology
    Ando M et al., 2003, Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults., J Epidemiol
    Ariyoshi N et al., 2002, Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers., Cancer Epidemiol Biomarkers Prev
    Daigo S et al., 2002, A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur., Pharmacogenetics
    Zhang X et al., 2001, Lack of association between smoking and CYP2A6 gene polymorphisms in A Japanese population., Nihon Arukoru Yakubutsu Igakkai Zasshi
    Tan W et al., 2001, Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population., Int J Cancer
    Ariyoshi N et al., 2001, A novel single nucleotide polymorphism altering stability and activity of CYP2a6., Biochem Biophys Res Commun
    Poland RE et al., 2000, Effect of cigarette smoking on coumarin metabolism in humans., Nicotine Tob Res
    Rao Y et al., 2000, Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking., Mol Pharmacol
    Wang J et al., 2006, 3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression., Biochem Biophys Res Commun
    Borrie AE et al., 2018, Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer., Breast Cancer Res Treat
    Desta Z et al., 2011, Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age., Clin Pharmacol Ther
    Nakajima M et al., 2004, Novel human CYP2A6 alleles confound gene deletion analysis., FEBS Lett
    Smith IE et al., 2003, Aromatase inhibitors in breast cancer., N Engl J Med
    Paschke T et al., 2001, Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method., Toxicology
    Kwon JT et al., 2001, Nicotine metabolism and CYP2A6 allele frequencies in Koreans., Pharmacogenetics
    Nakajima M et al., 2001, Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans., Clin Pharmacol Ther
    Lerman C et al., 2015, Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial., Lancet Respir Med
    Endo T et al., 2007, Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes., Drug Metab Dispos
  • LOSIGAMONE   CYP2A6

    Interaction Score: 18.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11038165 8886611 19702528 19442086 14704462 12386121


    Sources:
    PharmGKB

  • LETROZOLE   CYP2A6

    Interaction Score: 9.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30094551 21975350 10448083 9827545 21521021 21494765 20860463 20596643 20155256 20089352 19921195 19845430 19604090 19238117 19225447 18698229 18380793 18212800 17220563 17130279 17112802 16952495 16891249 16452582 16402128 16378601 16272956 15980104 15940289 15900015 15660270 15592323 15475735 15308589 15265511 15225612 14981342 12844137 12802030 12749606 12325023 12223434 12042667 11779172 11725533 11684323 11434509 11394901 11241319 11237731 11180041 10999944 10544257


    Sources:
    PharmGKB

  • PILOCARPINE   CYP2A6

    Interaction Score: 8.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10448083 21521021 21494765 20860463 20596643 20155256 20089352 19921195 19845430 19604090 19238117 19225447 18698229 18380793 18212800 17220563 17178767 17130279 17112802 16952495 16891249 16452582 16402128 16272956 15980104 15940289 15900015 15660270 15475735 15308589 15265511 14981342 12844137 12749606 12223434 12042667 11779172 11725533 11394901 11241319 11237731 10999944 10544257


    Sources:
    PharmGKB

  • 3-FORMYLINDOLE   CYP2A6

    Interaction Score: 5.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25458499


    Sources:
    DTC

  • CHEMBL1770735   CYP2A6

    Interaction Score: 5.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25458499


    Sources:
    DTC

  • CAFFEINE   CYP2A6

    Interaction Score: 4.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10448083 21521021 21494765 20860463 20596643 20155256 20089352 19921195 19845430 19604090 19238117 19225447 18698229 18380793 18212800 17267622 17220563 17130279 17112802 16952495 16891249 16452582 16402128 16272956 15980104 15940289 15900015 15660270 15592323 15475735 15308589 15265511 14981342 12844137 12749606 12223434 12042667 11779172 11725533 11394901 11241319 11237731 11197315 10999944 10544257


    Sources:
    PharmGKB

  • ARTEMETHER   CYP2A6

    Interaction Score: 4.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12844133 19926036 19851082 18979093 18350255 18064444 12920490


    Sources:
    PharmGKB

  • COUMARIN   CYP2A6

    Interaction Score: 4.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9827545 9409631 27339126 21521021 16679388 16041240 15900015 14583682 12844137 11779172 11394901 11278503 10923861 10544257 2322567 15993850 12325023 11038160


    Sources:
    PharmGKB

  • ARTEMISININ   CYP2A6

    Interaction Score: 2.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12844133 19926036 19851082 18979093 18350255 18064444 12920490


    Sources:
    PharmGKB

  • ARTESUNATE   CYP2A6

    Interaction Score: 2.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12844133 19926036 19851082 18979093 18350255 18064444 12920490


    Sources:
    PharmGKB

  • IFOSFAMIDE   CYP2A6

    Interaction Score: 2.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11038165 8886611 19702528 19442086 14704462 12386121


    Sources:
    PharmGKB

  • VARENICLINE   CYP2A6

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25588294


    Sources:
    PharmGKB

  • HALOTHANE   CYP2A6

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11038165 8886611 19702528 19442086 14704462 12386121


    Sources:
    PharmGKB

  • PHENYTOIN   CYP2A6

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11038165 8886611 19702528 19442086 14704462 12386121


    Sources:
    PharmGKB

  • CARBAMAZEPINE   CYP2A6

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11038165 8886611 19702528 19442086 14704462 12386121


    Sources:
    PharmGKB

  • METHOXSALEN   CYP2A6

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • BUPROPION   CYP2A6

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26132489


    Sources:
    PharmGKB

  • ESOMEPRAZOLE   CYP2A6

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   CYP2A6

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14981342 21521021 21494765 20155256 19921195 19604090 19238117 18698229 16378601 15940289


    Sources:
    PharmGKB

  • ACETAMINOPHEN   CYP2A6

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9548799 26049587 11866476


    Sources:
    PharmGKB

  • COTININE   CYP2A6

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CYCLOPHOSPHAMIDE   CYP2A6

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11038165 8886611 19702528 19442086 14704462 12386121


    Sources:
    PharmGKB

  • ZIDOVUDINE   CYP2A6

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22960662


    Sources:
    PharmGKB

  • DOCETAXEL   CYP2A6

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19604090


    Sources:
    PharmGKB

  • Ensembl: ENSG00000255974

    • Version: 101_38

    Alternate Names:
    CYP2A6 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000198470

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000198470 Ensembl Gene Id
    CYTOCHROME P450 2A6 (EC 1.14.14.1) (CYPIIA6) (COUMARIN 7-HYDROXYLASE) (IIA3) (CYP2A3) (P450(I)). [SOURCE:UNIPROT/SWISSPROT;ACC:P11509] Description
    CYP2A6 Display Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: P11509

    • Version: 11-September-2012

    Alternate Names:
    P11509 Uniprot Accession
    CYP2A6 Uniprot Gene Name
    ENSG00000255974 Ensembl Gene Id

    Gene Info:
    Interpro Name Cytochrome P450
    Uniprot Status Swiss-Prot
    Interpro Type Family

    Gene Categories:
    DRUGGABLE GENOME, CYTOCHROME P450

    Publications:

  • PharmGKB: CYP2A6

    • Version: 18-August-2020

    Alternate Names:
    PA121 PharmGKB ID

    Gene Info:

    Publications:
    Ghodke Y et al., 2012, PharmGKB summary: zidovudine pathway., Pharmacogenet Genomics
    Pearce RE et al., 2002, Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites., Drug Metab Dispos
    Di YM et al., 2009, Structure, function, regulation and polymorphism of human cytochrome P450 2A6., Curr Drug Metab

  • DTC: CYP2A6

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Tani N et al., 2014, Rational design of novel CYP2A6 inhibitors., Bioorg Med Chem

  • HingoraniCasas: ENSG00000255974

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000255974 Gene Symbol
    CYP2A6 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TTD: Cytochrome P450 2A6

    • Version: 2020.06.01

    Alternate Names:
    CYP2A6 TTD Gene Abbreviation
    T06455 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: CYP2A6

    • Version: 01-February-2022

    Alternate Names:
    Cytochrome P450 2A6 Gene Name
    P11509 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21